Meeting
2021 Genitourinary Cancers Symposium
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castrate-sensitive prostate cancer.
Authors
Mary Mahler
Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada
Mary Mahler , Esmail Mutahar Al-Ezzi , Noa Shani Shrem , Eric Winquist , Christina M. Canil , Michael Ong , Aaron Richard Hansen , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 117)
DOI
10.1200/JCO.2021.39.6_suppl.117
Abstract #
117
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2020 Genitourinary Cancers Symposium
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
First Author: Andrew Lachlan Schmidt
Poster
2020 Genitourinary Cancers Symposium
Radium-223 in the treatment of metastatic castrate-resistant prostate cancer: A real-world Irish experience.
First Author: Niamh Peters
Poster
2019 Genitourinary Cancers Symposium
Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive prostate cancer (mCSPC): A single institution experience.
First Author: Seanthel Delos Santos